Literature DB >> 17251987

Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

L Pereboeva1, S Komarova, J Roth, S Ponnazhagan, D T Curiel.   

Abstract

Adenovirus (Ad)-based vectors are useful gene delivery vehicles for a variety of applications. Despite their attractive properties, many in vivo applications require modulation of the viral tropism. Targeting approaches applied to adenoviral vectors included genetic modification of the viral capsid, controlled expression of the transgene and combinatorial approaches that combine two or more targeting elements in single vectors. Most of these studies confirmed successful retargeting in cell cultures, however, in vivo gains of targeted adenoviral vectors have not been widely demonstrated. We have developed a combinatorial retargeting approach utilizing metabolically biotinylated Ad, where the biotin acceptor peptide was incorporated in one of the fibers in a dual fiber viral particle resulting in metabolically biotinylated fiber-mosaic Ad (mBfMAd). We have utilized this vector in complex with epidermal growth factor (EGF)-Streptavidin to retarget fiber-mosaic virus to EGF receptor (EGFR) expressing cells in vitro and confirmed an increased infectivity of the retargeting complex. Most importantly, the utility of this strategy was demonstrated in vivo in two distinct animal models. In both models tested, retargeted mBfMAd demonstrated an increased ratio of gene expression in target tissues compared to the liver expression profile. Thus, metabolically biotinylated fiber-mosaic virus in combination with appropriate adapters can be successfully exploited for adenoviral retargeting strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251987      PMCID: PMC2203207          DOI: 10.1038/sj.gt.3302916

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  37 in total

1.  Biotination of proteins in vivo. A post-translational modification to label, purify, and study proteins.

Authors:  J E Cronan
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

Review 2.  Protein tyrosine kinases and cancer.

Authors:  K S Kolibaba; B J Druker
Journal:  Biochim Biophys Acta       Date:  1997-12-09

3.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

Authors:  T J Wickham; E Tzeng; L L Shears; P W Roelvink; Y Li; G M Lee; D E Brough; A Lizonova; I Kovesdi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice.

Authors:  D L Gu; A M Gonzalez; M A Printz; J Doukas; W Ying; M D'Andrea; D K Hoganson; D T Curiel; J T Douglas; B A Sosnowski; A Baird; S L Aukerman; G F Pierce
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

5.  Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors.

Authors:  M Everts; S-A Kim-Park; M A Preuss; M J Passineau; J N Glasgow; A V Pereboev; P J Mahasreshti; W E Grizzle; P N Reynolds; D T Curiel
Journal:  Gene Ther       Date:  2005-07       Impact factor: 5.250

6.  The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery.

Authors:  S J Watkins; V V Mesyanzhinov; L P Kurochkina; R E Hawkins
Journal:  Gene Ther       Date:  1997-10       Impact factor: 5.250

7.  Noninvasive of adenovirus tumor retargeting in living subjects by a soluble adenovirus receptor-epidermal growth factor (sCAR-EGF) fusion protein.

Authors:  Qianwa Liang; Igor Dmitriev; Elena Kashentseva; David T Curiel; Harvey R Herschman
Journal:  Mol Imaging Biol       Date:  2004 Nov-Dec       Impact factor: 3.488

8.  Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.

Authors:  C Rancourt; B E Rogers; B A Sosnowski; M Wang; A Piché; G F Pierce; R D Alvarez; G P Siegal; J T Douglas; D T Curiel
Journal:  Clin Cancer Res       Date:  1998-10       Impact factor: 12.531

9.  An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism.

Authors:  I Dmitriev; V Krasnykh; C R Miller; M Wang; E Kashentseva; G Mikheeva; N Belousova; D T Curiel
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Recombinant core streptavidins. A minimum-sized core streptavidin has enhanced structural stability and higher accessibility to biotinylated macromolecules.

Authors:  T Sano; M W Pandori; X Chen; C L Smith; C R Cantor
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

View more
  13 in total

1.  PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors.

Authors:  Galith Abourbeh; Alexei Shir; Eyal Mishani; Manfred Ogris; Wolfgang Rödl; Ernst Wagner; Alexander Levitzki
Journal:  IUBMB Life       Date:  2012-02-23       Impact factor: 3.885

2.  Unnatural amino acid incorporation onto adenoviral (Ad) coat proteins facilitates chemoselective modification and retargeting of Ad type 5 vectors.

Authors:  Partha Sarathi Banerjee; Philomena Ostapchuk; Patrick Hearing; Isaac Sheridan Carrico
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

Review 3.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 4.  Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices.

Authors:  Maria Yanqing Chen; Susan S Butler; Weitong Chen; Junghae Suh
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-11-08

5.  Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation.

Authors:  A Schäfer; A Pahnke; D Schaffert; W M van Weerden; C M A de Ridder; W Rödl; A Vetter; C Spitzweg; R Kraaij; E Wagner; Manfred Ogris
Journal:  Hum Gene Ther       Date:  2011-08-10       Impact factor: 5.695

6.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

7.  A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.

Authors:  Kouki Morizono; Yiming Xie; Gustavo Helguera; Tracy R Daniels; Timothy F Lane; Manuel L Penichet; Irvin S Y Chen
Journal:  J Gene Med       Date:  2009-08       Impact factor: 4.565

8.  Targeted noninvasive imaging of EGFR-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography.

Authors:  Shanice V Hudson; Justin S Huang; Wenyuan Yin; Sabrin Albeituni; Jamie Rush; Anil Khanal; Jun Yan; Brian P Ceresa; Hermann B Frieboes; Lacey R McNally
Journal:  Cancer Res       Date:  2014-09-12       Impact factor: 12.701

9.  Low-Affinity Neurotrophin Receptor p75 Promotes the Transduction of Targeted Lentiviral Vectors to Cholinergic Neurons of Rat Basal Forebrain.

Authors:  Inga Antyborzec; Valerie B O'Leary; James O Dolly; Saak V Ovsepian
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

10.  A potential approach for assessing the quality of human and nonhuman adenoviral vector preparations.

Authors:  Ekramy E Sayedahmed; Suresh K Mittal
Journal:  Can J Vet Res       Date:  2020-10       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.